The global market for COVID-19 saliva sampling tests is projected to grow from USD 3,671.4 million in 2024 to USD 5,382.5 million by 2034, according to the latest industry analysis. This marks a steady compound annual growth rate (CAGR) of 3.9% over the forecast period. In 2023, the market recorded a revenue of USD 3,533.6 million and is expected to see year-on-year (Y-o-Y) growth of 3.8% in 2024, reflecting increased adoption of non-invasive testing solutions.
COVID-19 saliva sampling tests offer a more convenient, non-invasive alternative to traditional nasal swab tests, making them a preferred option for use in schools, workplaces, and public events. Their simplicity of use and enhanced accessibility have significantly contributed to their rising demand. As testing needs evolve globally, the market is expected to see further expansion driven by increased consumer preference for user-friendly testing methods.
Market growth is further fueled by technological advancements in molecular diagnostics, which continue to enhance the accuracy and speed of saliva-based testing. The convenience of rapid results has made these tests essential for ongoing COVID-19 monitoring, especially in high-traffic public areas. Additionally, shifting public health strategies and the continued need for infection rate monitoring, even in vaccinated populations, are providing sustained momentum for the market’s growth.
With the demand for non-invasive, comfortable testing options rising steadily, industry stakeholders are poised to capitalize on this growth trajectory. As regulatory frameworks evolve and innovations in molecular diagnostics continue, the COVID-19 saliva sampling test market is expected to maintain its upward momentum, offering both healthcare providers and consumers a reliable and efficient testing alternative.
A Full Report Overview – https://www.futuremarketinsights.com/reports/covid-19-saliva-sampling-test-potential-market
Key Takeaways:
- The COVID-19 saliva sampling test market is projected to grow at a 3.9% CAGR, from USD 3,671.4 million in 2024 to USD 5,382.5 million by 2034.
- Non-invasive testing methods are driving market demand, with increased use in schools, workplaces, and public events.
- Technological advancements in molecular diagnostics and the need for rapid, user-friendly testing options are key market drivers.
- Shifting public health strategies and ongoing monitoring of COVID-19 infection rates are supporting continued market growth.
Key drivers of market growth include:
- Increased Demand for Comfort-Friendly Testing: The preference for non-invasive testing options is rising as individuals seek more comfortable alternatives.
- Advancements in Molecular Diagnostics: Technological innovations are improving the accuracy and efficiency of saliva testing.
- Rapid Results: The ability to deliver quick results is crucial in managing public health responses.
Additionally, the ongoing vaccination efforts and evolving public health strategies for monitoring COVID-19 infection rates are contributing factors to the market’s expansion.
The growth of the COVID-19 saliva sampling test market is driven by several key factors:
- Non-Invasive Testing: Saliva tests are significantly less invasive compared to traditional nasal swabs, making them more comfortable and acceptable for patients. This ease of collection encourages higher participation rates, especially in mass testing scenarios such as schools and public events
- Technological Advancements: Innovations in molecular diagnostics, including CRISPR-based technologies and fluorescence-labeled antigen/antibody testing, have enhanced the accuracy and efficiency of saliva tests. These advancements support the rapid development and deployment of effective testing solutions
- Government Support: Increased investment and promotion from government agencies have bolstered the adoption of saliva-based tests. Collaborations between public health organizations and private companies have facilitated the expansion of testing capacities, particularly in areas with high infection rates
- Cost-Effectiveness: Saliva sampling tests generally require fewer resources than traditional methods, leading to lower operational costs. This affordability makes regular testing more accessible for schools, businesses, and healthcare providers, promoting widespread adoption
Competitive Landscape
Key players operating in the COVID-19 saliva sampling test potential cover market are investing in development of advanced and innovative products that are more reliable and efficient. Also, many of the key players are emphasizing on making strategic collaborations and acquisition for expansion of their geographical presence and strengthening their market share.
Recent Industry Developments in COVID-19 Saliva Sampling Test Potential Market
- In April 2023, The Center for the Biomedical Advanced Research and Development Authority (BARDA) collaborated with Aptitude Medical Systems, Inc. for accelerating the development of molecular diagnostic tests for COVID-19. These metrix test enables use of saliva samples for as clinical specimen and improves accessibility to high quality diagnostics.
- In June 2020, The Regents of the University of California launched trials for saliva tests for COVID-19.
Key Players of COVID-19 Saliva Sampling Test Potential Industry
- ARUP Laboratories
- Vatic Health
- Mogene
- Psomagen Inc
- DxTerity Diagnostics Inc
- Chembio Diagnostics
- Abbott
Key Segments of COVID-19 Saliva Sampling Test Potential Industry
By Location:
In terms of Location, the industry is divided into travel stations, sports arenas, entertainment venues, corporate campus environments, universities & colleges and factories
By Technology:
In terms of technology, the industry is divided into fluorescence-labeled antigen/antibodies testing, RT-PCR, CRISPR-Cas9
By Mode:
In terms of mode, the industry is segregated into centralized testing and decentralized testing
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and Middle East and Africa (MEA), have been covered in the report.
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Diabetic Macular Edema Industry
Dermal Fillers and Botulinum Toxin Indusrty
Bioabsorbable Stents Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube